SLC6A3 rs2220330: Understanding Dopamine Transporter Variants
The rs2220330 variant is a genetic change located within the SLC6A3 gene, which encodes the dopamine transporter protein. Researchers study this variant to understand if it influences how individuals respond to methylphenidate, a medication often used for ADHD.
What each genotype means
Typical dopamine transporter profile
This genotype is associated with the SLC6A3 gene, which encodes the dopamine transporter protein. Research into this specific variant often focuses on how it may influence individual responses to methylphenidate treatment, though findings remain mixed and sometimes contradictory across different studies. Please discuss your treatment plan and any medication dosing questions with your clinician or pharmacist.
This genotype is common in many global populations, though exact frequencies vary significantly by ancestry.
Typical dopamine transporter profile
This genotype is associated with the SLC6A3 gene, which encodes the dopamine transporter protein. Research into this specific variant often focuses on how it may influence individual responses to methylphenidate treatment, though findings remain mixed and sometimes contradictory across different studies. Please discuss your treatment plan and any medication dosing questions with your clinician or pharmacist.
This genotype is common in many global populations, though exact frequencies vary significantly by ancestry.
Typical dopamine transporter profile
This genotype is associated with the SLC6A3 gene, which encodes the dopamine transporter protein. Research into this specific variant often focuses on how it may influence individual responses to methylphenidate treatment, though findings remain mixed and sometimes contradictory across different studies. Please discuss your treatment plan and any medication dosing questions with your clinician or pharmacist.
This genotype is common in many global populations, though exact frequencies vary significantly by ancestry.
What is the rs2220330 Variant?
The rs2220330 variant is a single-nucleotide polymorphism (SNP) found within the SLC6A3 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant is located in a region of the gene that researchers monitor for potential functional impacts on protein expression or regulation. Because the SLC6A3 gene is responsible for the production of the dopamine transporter, scientists are interested in whether variations like rs2220330 alter the efficiency of dopamine regulation in the brain. While many SNPs exist throughout the human genome, those located within genes that manage neurotransmitters are frequently investigated for their potential to influence behavioral traits or responses to pharmacological interventions.
The Role of the SLC6A3 Gene
The SLC6A3 gene provides instructions for making the dopamine transporter, a protein that resides on the surface of nerve cells. Its primary function is to clear dopamine from the synaptic cleft—the space between neurons—back into the cell that released it. This process, known as reuptake, is essential for maintaining the correct balance of dopamine, a neurotransmitter critical for mood, motivation, and attention. When the dopamine transporter is functioning normally, it helps regulate the duration and intensity of dopamine signaling. Because of its central role in dopamine homeostasis, the SLC6A3 gene is a primary candidate for research into neuropsychiatric conditions, including ADHD, where dopamine signaling is often a focus of therapeutic strategies.
Research and Evidence Strength
Research into rs2220330 and its clinical implications is currently categorized as having limited evidence. While the SLC6A3 gene is widely recognized as a key player in dopamine regulation, studies attempting to link specific SNPs like rs2220330 to consistent differences in methylphenidate response have produced mixed results. Some studies suggest that genetic variations in this gene may act as modifiers for how well a patient responds to stimulant medications, but these findings are often dependent on the specific population studied and the methodology used. Because of the complexity of ADHD and the multiple genes involved in neurotransmitter pathways, it is difficult to isolate the effect of a single variant. Consequently, current scientific consensus does not support using this variant as a definitive predictor for clinical treatment decisions.
Population Frequency
The rs2220330 variant is considered a common genetic marker. It is found across diverse human populations, though the specific frequency of the alleles can vary significantly depending on ancestral background. Large-scale genomic databases indicate that this variant is widely distributed, meaning that a large portion of the global population carries one or more copies of the variant alleles. This high prevalence is typical for many SNPs that do not have a severe impact on survival or reproductive fitness. Because it is common, researchers often use it in large-scale association studies to see if it correlates with specific traits, though its commonality also means that it is unlikely to be the sole cause of any complex medical condition.
What You Can Do With This Information
Understanding your genetic variants can be an educational experience, but it is important to recognize the limitations of current research. Genetic information regarding pharmacogenomics, such as the study of rs2220330, is intended for research purposes and should not be used to make personal medical decisions. You cannot use this information to diagnose a condition or to determine if a medication will be effective for you. If you have questions about your treatment plan, the dosage of your medication, or how your genetics might influence your health, you must discuss these topics with your clinician or a qualified pharmacist. They are the only ones who can interpret your health history and clinical needs to provide appropriate medical guidance.
How common is this variant?
The rs2220330 variant is a common polymorphism found across diverse global populations, with its specific allele frequencies varying by ancestry.
Frequently asked questions
Can I use rs2220330 to predict if ADHD medication will work?
No. Current evidence for this variant is limited and inconsistent. It cannot be used to predict individual responses to medication, and you should always consult your doctor regarding treatment.
Is rs2220330 a diagnostic test for ADHD?
No. ADHD is a complex condition influenced by many genetic and environmental factors. A single SNP like rs2220330 is not a diagnostic tool for any medical condition.
Where can I find more information about SLC6A3?
You can explore resources like MedlinePlus Genetics or the NCBI Gene database for comprehensive, peer-reviewed information on the function and clinical significance of the SLC6A3 gene.
Should I change my medication based on my genotype?
Absolutely not. Never change your medication dosage or stop taking a prescribed treatment based on genetic test results without speaking to your healthcare provider first.
Sources & further reading
Educational information only, last refreshed 10/1/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2220330?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SLC6A3
This SNP is part of a haplotype associated with treatment failure in patients receiving methylphenidate therapy.
A tag SNP correlated with functional dopamine active transporter expression patterns during acute cognitive and psychological stress challenges.
This variant in the dopamine transporter gene is linked to various behavioral and psychiatric traits.